Other Routes of Protein and Peptide Delivery: Transdermal, Topical, Uterine, and Rectal - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 663

permeability of growth hormone releasing peptide, mannitol, and lucifer yellow. Pharm
Res 1993;10:553-61.
[148] Golomb G, Shaked I, Hoffman A. Intrauterine administration of peptide drugs for sys-
temic effect. Adv Drug Deliv Rev 1995;17:179-90.
[149] Hoffman A, Shaked I, Avramoff A, Golomb G. Pharmacokinetics and pharmacodynam-
ics of trans-endometrial administered peptides and macromolecules. Adv Drug Deliv
Rev 1995;17:191-203.
[150] Sumner DR, Turner TM, Purchio AF, Gombotz WR, Urban RM, Galante JO. Enhancement
of bone in growth by transforming growth factor-beta. J Bone Joint Surg 1995;77:
1135-47.
[151] Matuszewska B, Keogan M, Fisher DM, Soper KA, Hoe C-MA, et al. Acidic fibroblast
growth factor: evaluation of topical formulations in a diabetic mouse wound healing
model. Pharm Res 1994;11:65-71.
[152] Shimizu K, Nishikawa T, Nozaki M, Oshima K. Effects of an intrauterine copper device
on serum copper, endometrial histology and ovarian, hepatic, and renal functions in the
Japanese monkey ( Macaca fuscata fuscata ). J Med Primatol 1991;20:277-83.
[153] Chi IC. The Nova-T IUD—a review of the literature. Contraception 1991;44:341-66.
[154] World Health Organization (WHO). The IUD—worth singing about. WHO Progress in
Reproductive Health Research 2002;60:1-8.
[155] Susan R, Chaudhari A, Peterson C. Mirena ® (Levonorgestrel intrauterine system): a suc-
cessful novel drug delivery option in contraception. Adv Drug Deliv Rev 2009;61:808-12.
[156] Smith B, Uhl K. Drug delivery in twenty-first century: a new paradigm. Clin Pharmacol
Ther 2009;85:451-5.
[157] Van Os W, Edelman D. New directions in IUCD development. Adv Contracept
1998;14:41-4.
[158] Wildemeersch D, Batár I, Webb A, Gbolade BA, Delbarge W, Temmerman M, et al.
GyneFIX. The frameless intrauterine contraceptive implant—an update for interval,
emergency and postabortal contraception. Br J Fam Plann 1999;24:149-59.
[159] de Leede LGJ, Hug CC Jr, De Lange S, de Boer AG, Breimer DD. Rectal and intra-
venous infusion of propranolo1 to steady-state; kinetics and -receptor blockade. Clin
Pharmacol Ther Ser 1984;35:l48-55.
[160] Kleinbloesem CH, van Brummelen P, van Linde JA, de Voogd JA, Breimer DD.
Nifedipine kinetic and hemodynamic during rectal infusion to steady-state with an
osmotic system. Clin Pharmacol Ther Ser 1984;36:396-401.
[161] Kleinbloesem CH, van Brummelen P, van Linde JA, de Voogd JA, Breimer DD.
Nifedipine kinetic and hemodynamic during rectal infusion to steady-state with an
osmotic system. Clin Pharmacol Ther Ser 1984;35:742-9.
[162] Miyake M, Nishihata T, Nagantr A, Kyohahi Y, Kamada A. Rectal absorption of [Asu
1,7]-eel calcitonln in rat. Chem Pharm Bull 1985;33:740-5.
[163] Morimoto K, Ahatauchi H, Morisaka K., Karnada A. Effect of non-ionic surfactants in
a polyacrylic acid gel base on the rectal absorption of [Asu 1,7 ]-eel calcitonln in rat.
J Pharm Pharmacol 1985;37:759-60.
[164] van Hoogdalem EJ, Heijiliger-Feijien CD, Mathot RA, Wackwit AT, van Brec JB, et al.
Rectal absorption enhancement of cefoxitin and desglycinamide arginine vasopressin by
sodium tauro-24, 25-dihydrofusidate in conscious rat. J Pharmacol Exp Ther 1989;251:
741-4.
[165] van Hoogdalem EJ, Heijiliger-Feijien CD, Verhoef JC, de Boer AG, Breimer DD.
Absorption enhancement of rectally infused insulin by sodium tauro-24, 25-dihydrofu-
sidate (STDHF) in rats. Pharm Res 1990;7:180-3.